CHICAGO--(BUSINESS WIRE)--Serious Adverse Events Consortium:
WHAT: The Serious Adverse Events Consortium (SAEC), a nonprofit partnership between several leading pharmaceutical companies and academic institutions, with scientific and strategic input from the U.S. Food and Drug Administration (FDA), is hosting a teleconference to announce the launch of two initial research programs designed to identify genetic markers that may help predict which individuals are at risk for serious drug-related adverse events (SAEs).
